2023
Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group
Mailhot Vega R, Harker-Murray P, Forlenza C, Cole P, Kelly K, Milgrom S, Parikh R, Hodgson D, Castellino S, Kahn J, Roberts K, Constine L, Hoppe B. Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: 400-403. PMID: 37116589, PMCID: PMC10655744, DOI: 10.1016/j.ijrobp.2023.04.022.Peer-Reviewed Original ResearchConceptsOncology GroupYoung adult Hodgkin lymphomaAdult Hodgkin lymphomaChildren's Oncology GroupRadiation therapy useTherapy useHodgkin's lymphomaLymphoma
2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIBThe Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Herrera A, Friedberg J, Friedman D, Schwartz C, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity. Blood 2021, 138: 881. DOI: 10.1182/blood-2021-147678.Peer-Reviewed Original ResearchInvolved site radiotherapyCardiac radiation doseInvolved-field radiotherapyChildhood Cancer Survivor StudyPositron emission tomographyMediastinal radiotherapyChildren's Oncology GroupDoxorubicin doseCumulative incidenceCardiac toxicityCardiac diseaseRT useCardiac riskCardiac disease riskBulk diseaseOncology GroupLymphoma trialsTrial protocolRadiation doseLong-term cardiac riskDisease riskCumulative doxorubicin doseImpact of nivolumabLate cardiac toxicityMean heart dosePediatric classical Hodgkin lymphoma
Lo AC, Dieckmann K, Pelz T, Gallop‐Evans E, Engenhart‐Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatric Blood & Cancer 2021, 68: e28562. PMID: 33818890, DOI: 10.1002/pbc.28562.Peer-Reviewed Original ResearchConceptsClassical Hodgkin lymphomaChildren's Oncology GroupPediatric classical Hodgkin lymphomaHodgkin's lymphomaRadiation therapyOncology GroupUtilization of RTHigh-risk patientsBulk of diseaseHigh cure ratesUniformly fatal diseaseLong-term toxicityIntensity of treatmentEuroNet-PHLB symptomsRisk patientsCurable cancerLymphoma trialsRT volumeCure rateTumor stageImmunoregulatory drugsTrial groupChemotherapy agentsHL management
2020
Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group
Parikh R, Hoppe B, Hodgson D, McCarten K, Pei Q, Cho S, Schwartz C, Cole P, Kelly K, Roberts K. Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s36-s37. DOI: 10.1016/j.ijrobp.2020.07.2140.Peer-Reviewed Original Research
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2015
Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group
Kelly K, Cole P, Chen L, Roberts K, Hodgson D, McCarten K, Cho S, Schwartz C. Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. Blood 2015, 126: 3927. DOI: 10.1182/blood.v126.23.3927.3927.Peer-Reviewed Original ResearchHigh-risk Hodgkin lymphomaRapid early responseCompletion of chemotherapyABVE-PCStage IIIBOncology GroupOverall survivalPediatric patientsHodgkin's lymphomaHigh riskLong-term overall survivalDose-intensive chemotherapyRisk-adapted radiotherapyEnd of chemotherapyEvent-free survivalBone marrow involvementPhase III studyRelapse/progressionBest predictive factorChildren's Oncology GroupHigh-risk groupEnhanced risk stratificationTreatment of childrenPET-positive lesionsBulky involvement